REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY
Alejandro Garrido 1
Isabel Iborra colomino 2
Berta Caballol Oliva 3
Jose Maria Huguet 4
Lara Arias García 5
Francisco Mesonero Gismero 6
Samuel Fernández Prada 7
Marta Maia Boscá Watts 8
Ángel Ponferrada-Díaz 9
Xavier Calvet Calvo 10
Ana Gutiérrez-Casbas 11
Ingrid Ordás 12
Lucía Ruiz Sánchez 12
Beatriz Sicilia Aladrén 12
Irene García de la filia Molina 13
Eugeni Domenech Morral 14
Pilar Nos Mateu 15
1 Hospital Universitari i Politècnic La Fe (Valencia), Valencia, Spain
2 Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain
3 Hospital Clinic de Barcelona, Barcelona, Spain
4 Consorcio Hospital General Universitario de Valencia, Valencia, Spain
5 Hospital Universitario de Burgos, Burgos, Spain
6 Hospital Ramon y Cajal, Los Santos de la Humosa, Spain
7 Hospital Universitario Río Hortega de Valladolid, Valladolid, Spain
8 Hospital Clínico Universitario de Valencia, Valencia, Spain
9 Hospital Infanta Leonor, Madrid, Spain
10 Hospital de Sabadell, Institut Universitari Parc Tauli, UAB, Barcelona, Spain
11 Hospital General Universitario Alicante, Alicante, Spain
12 Hospital Clinic of Barcelona, Barcelona, Spain
13 Hospital Universitario Ramón y Cajal, Madrid, Spain
14 Hospital Germans Trias i pujol, Badalona, Barcelona, Spain
15 Hospital La Fe, Valencia, Spain
Topic
IBD
Session
PP 05 IBD (Posters)
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]